5-(3-quinolyl)tetrazole | 13566-36-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-(3-quinolyl)tetrazole
• 英文别名: 3-(1(2)H-tetrazol-5-yl)-quinoline；3-(2H-tetrazole-5-yl)-quinoline；3-(2H-tetrazol-5-yl)quinoline
• CAS: 13566-36-4
• 化学式: C₁₀H₇N₅
• 分子量: 197.199
• InChiKey: NCTWQUYOOHAZLQ-UHFFFAOYSA-N

物化性质

• 沸点：
  459.5±47.0 °C(Predicted)
• 密度：
  1.408±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  间苯二甲酰氯 、 5-(3-quinolyl)tetrazole 在 吡啶 作用下， 反应 3.0h， 以82%的产率得到1,3-bis[2-(quinoline-3-yl)-1,3,4-oxadiazole-5-yl]benzene
  参考文献：
  名称：

  EP1932842

  摘要：

  公开号：
• 作为产物：
  描述：

  3-氰基喹啉 在 sodium azide 、 氯化铵 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 240.0h， 以92%的产率得到5-(3-quinolyl)tetrazole
  参考文献：
  名称：

  固体闪蒸真空热解法将4-喹啉卡宾，3-喹啉卡宾和2-喹啉卡宾重排为1-萘基丁烯和氰基茚

  摘要：

  4- quinolylcarbene之间的关系17，3- quinolylcarbene 21，2-quinolylcarbene 25，和1- naphthylnitrene 35已通过实验和计算上的探讨。通过红外光谱法观察了由（5-四唑基）喹啉或1,2,3-三唑并[1,5- a ]喹啉通过常规快速真空热解（FVP）产生的重氮甲基喹啉。通过降落的固体闪蒸真空热解法（FS-FVP）生成了卡宾。4- Quinolylcarbene 17发现要重新排列到3- quinolylcarbene 21，然后到2- quinolylcarbene 25，最后经由1- naphthylnitrene 35至1-cyanoindene 36，然后异构化为3-和2-氰基茚12和13。通过ESR光谱法证实了2-喹啉基卡宾向1-萘基硝烯的热重排。通过计算喹啉基碳烯和1-萘基氮烯以及间插的氮杂-苯并双环[4.1.

  DOI：

  10.1021/acs.joc.6b00444

文献信息

• Development and Demonstration of a Safer Protocol for the Synthesis of 5-Aryltetrazoles from Aryl Nitriles
  作者：Daniel S. Treitler、Simon Leung、Mark Lindrud

  DOI：10.1021/acs.oprd.7b00016

  日期：2017.3.17

  for a faster, safer protocol for the direct synthesis of 5-aryltetrazoles from aryl nitriles in the presence of sodium azide and an amine hydrochloride salt led to the discovery of a buffered system comprised of BnNH2, BnNH2·HCl, and NaN3. After optimization of reaction conditions and a thorough investigation of reaction safety, the procedure was demonstrated for the synthesis of several hundred grams

  在叠氮化钠和胺盐酸盐存在下，寻找一种从芳基腈直接合成5-芳基四唑的更快，更安全的方法，导致发现了由BnNH 2，BnNH 2 ·HCl和NaN组成的缓冲体系。3。的反应条件和反应安全彻查优化之后，该过程被证明为几百克4-氯-2-（2-合成ħ -四唑-5-基）苯酚。通过使用16种额外的芳基和杂芳基腈底物进行小规模反应筛查，确定了开发的反应条件的一般性。
• COMPOUND HAVING OXADIAZOLE RING STRUCTURE BONDED WITH AROMATIC HETEROCYCLIC RING AND ORGANIC ELECTROLUMINESCENT DEVICE
  申请人：Miki Tetsuzo

  公开号：US20090230849A1

  公开（公告）日：2009-09-17

  An object of the invention is to provide an organic compound having excellent characteristics as a material for highly efficient and highly durable organic EL devices, and also to provide a highly efficient and highly durable organic EL device. This invention relates to a compound represented by the general formula (1) having an oxadiazole ring structure bonded with an aromatic heterocycle, and to an organic electroluminescence device containing the compound: wherein Ar represents a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted condensed polycyclic aromatic group; A represents a substituted or unsubstituted aromatic heterocyclic group; and n represents an integer of 1 to 3.

  本发明的目的是提供一种有机化合物，作为高效和高耐久性有机EL器件的材料具有优异的特性，同时提供一种高效和高耐久性的有机EL器件。本发明涉及一种由具有与芳香族杂环键合的噁唑环结构的通式（1）所表示的化合物，以及含有该化合物的有机电致发光器件：其中Ar代表取代或未取代的芳香族碳氢化合物基团，取代或未取代的芳香族杂环基团或取代或未取代的紧缩多环芳香族基团；A代表取代或未取代的芳香族杂环基团；n代表1至3的整数。
• Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists
  申请人：Behan Dominic P.

  公开号：US20080139628A1

  公开（公告）日：2008-06-12

  The invention provides a method of reducing flushing induced by niacin or a niacin analog in a subject, comprising administering to said subject an effective flush reducing amount of a niacin receptor partial agonist. In addition, the invention provides a method of reducing flushing induced by niacin or a niacin analog in a subject, comprising administering to said subject an effective flush reducing amount of a niacin receptor partial agonist and an effective lipid altering amount of niacin or a niacin analog. The invention further provides a method of reducing flushing induced by niacin or a niacin analog in a subject, comprising administering to said subject an effective flush reducing amount of a niacin receptor partial agonist and subsequently administering to said subject an effective lipid altering amount of niacin or a niacin analog.

  本发明提供了一种减少烟酸或烟酸类似物引起的面红的方法，包括向该受体中注射有效减少面红量的烟酸受体部分激动剂。此外，本发明还提供了一种减少烟酸或烟酸类似物引起的面红的方法，包括向该受体中注射有效减少面红量的烟酸受体部分激动剂和有效改变脂质含量的烟酸或烟酸类似物。本发明进一步提供了一种减少烟酸或烟酸类似物引起的面红的方法，包括向该受体中注射有效减少面红量的烟酸受体部分激动剂，然后向该受体中注射有效改变脂质含量的烟酸或烟酸类似物。
• Compound having oxadiazole ring structure bonded with aromatic heterocyclic ring and organic electroluminescent device
  申请人：Hodogaya Chemical Co., Ltd.

  公开号：US08247087B2

  公开（公告）日：2012-08-21

  An object of the invention is to provide an organic compound having excellent characteristics as a material for highly efficient and highly durable organic EL devices, and also to provide a highly efficient and highly durable organic EL device. This invention relates to a compound represented by the general formula (1) having an oxadiazole ring structure bonded with an aromatic heterocycle, and to an organic electroluminescence device containing the compound: wherein Ar represents a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted condensed polycyclic aromatic group; A represents a substituted or unsubstituted aromatic heterocyclic group; and n represents an integer of 1 to 3.

  本发明的目的是提供一种有机化合物，作为高效和高耐久性有机EL器件的材料具有优异的特性，并提供一种高效和高耐久性的有机EL器件。本发明涉及一种由一般式（1）表示的化合物，其具有与芳香杂环键合的噁唑环结构，并且涉及含有该化合物的有机电致发光器件：其中Ar代表取代或未取代的芳香烃基，取代或未取代的芳香杂环基或取代或未取代的紧缩多环芳香基；A代表取代或未取代的芳香杂环基；n代表1至3的整数。
• Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US20040142377A1

  公开（公告）日：2004-07-22

  The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.

  本发明涉及鉴定候选化合物是否为 G 蛋白偶联受体（GPCR）调节剂的方法。在优选的实施方案中，GPCR 是人类的。在其他优选的实施方案中，GPCR 与 Gi 相耦合，降低细胞内 cAMP 的水平。在其他优选的实施方案中，GPCR 由脂肪细胞内源表达。在更多优选的实施方案中，GPCR 可抑制细胞内脂肪分解。在其他更优选的实施方案中，GPCR 是烟酸受体。本发明还涉及使用所述 GPCR 的调节剂的方法。优选的调节剂是激动剂。本发明的激动剂可用作预防或治疗代谢相关疾病的治疗剂，包括血脂异常、动脉粥样硬化、冠心病、中风、胰岛素抵抗和 2 型糖尿病。